SEATTLE, WA -- (Marketwire) -- 01/03/12 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that the Nasdaq Hearings Panel has determined to delist the Company's common stock from the...
SAN FRANCISCO, CA -- (Marketwire) -- 11/21/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that its shareholders have approved proposals to complete the previously announced...
NEW YORK, NY -- (Marketwire) -- 11/21/11 -- Today, www.BollingerReport.com introduced featured coverage of Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) and Gilead Sciences, Inc. (NASDAQ: GILD...
SAN FRANCISCO, CA -- (Marketwire) -- 11/18/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it has...
SAN FRANCISCO, CA -- (Marketwire) -- 11/09/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that ISS Proxy Advisory Services, the nation's leading independent proxy advisory...
SAN FRANCISCO, CA -- (Marketwire) -- 11/07/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that Glass, Lewis & Co., a leading independent proxy advisory firm, has recommended...
SAN FRANCISCO, CA -- (Marketwire) -- 10/28/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial...
SAN FRANCISCO, CA -- (Marketwire) -- 10/28/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that Egan-Jones Proxy Services, an independent proxy advisory firm, has recommended...
The following table includes registration statements and post-effective amendments that were declared effective by the Securities and Exchange Commission on the most recently completed business...
SAN FRANCISCO, CA -- (Marketwire) -- 10/07/11 -- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.